FT. MYERS, FL / ACCESSWIRE / March 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host an Investor Day on Tuesday, April 4, 2023, starting at 8:00 am ET. The event will feature a presentation by NeoGenomics' executive team members and conclude with a Q&A session.
Pre-register for the event here. A live webcast of the Investor Day presentation will be available online on the investor relations page of the Company's website at ir.neogenomics.com. A replay will be posted on NeoGenomics' website after the event and will be available for at least 30 days following.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all applicable state and federal data protection laws, provides transparency and choice to patients regarding the handling and use of their data through expressed authorizations and our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, UK, Rolle, Switzerland, and China. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Contact:
NeoGenomics, Inc.
Kendra Sweeney
Vice President, Investor Relations and Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
T: +1-239-877-7474
| Last Trade: | US$16.04 |
| Daily Change: | -0.17 -1.05 |
| Daily Volume: | 462,685 |
| Market Cap: | US$2.060B |
July 29, 2024 April 30, 2024 April 18, 2024 March 27, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
